Gilman Hill Asset Management’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Gilman Hill Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,000	Closed	-$104K	–	178
2017 Q3	$104K	Buy	+5,000	New	+$120K	0.04%	165

Other funds holding ZBIO

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gilman Hill Asset Management's ZBIO Position: Q4 2017 in Review

Gilman Hill Asset Management sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q4 2017, closing a stake of 5,000 shares — an estimated $104K sold.

Gilman Hill Asset Management first reported a position in ZBIO in Q3 2017 and held it in 1 quarter. The position peaked at $104K in Q3 2017. 5 funds tracked by Wall St. Rank hold ZBIO as of Q4 2017.

Gilman Hill Asset Management reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q4 2017 after selling out during the quarter.
Gilman Hill Asset Management sold 5,000 ProShares UltraPro Short NASDAQ Biotechnology shares in Q4 2017, an estimated $104K.
Gilman Hill Asset Management first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q3 2017 and held it in 1 quarter.
Gilman Hill Asset Management's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $104K in Q3 2017.
5 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q4 2017.

Based on Gilman Hill Asset Management's 13F filing for Q4 2017, filed 30 Jan 2018.